Skip to main content

Advertisement

SpringerLink
Log in

Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer

  • Review
  • Published:
Tumor Biology

Abstract

Non-small cell lung cancer (NSCLC) is the common type of lung cancer, which is the leading cause of cancer death throughout the world. Most patients were diagnosed too late for curative treatment. So, it is necessary to develop a minimal invasive method to identify NSCLC at an early stage. In recent years, cell-free circulating tumor DNA (ctDNA) has attracted increasing attention as a potential tumor marker for its minimal invasive, convenient, and easily accepted properties. The amount of ctDNA in plasma or serum was significantly higher in NSCLC patients than that in healthy controls or patients with benign diseases. Furthermore, many studies have proved an association among tumor stage, tumor grade, lymph node involvement, the number of metastatic sites, tumor response, survival outcome, and the ctDNA levels. Many genetic changes, such as gene mutation, loss of heterozygosity, microsatellite instability, and gene methylation were also found in ctDNA in NSCLC patients. These findings demonstrated that the ctDNA could serve as a viable tool to monitor NSCLC and prompted us to find more sensitive and specific biomarkers for clinical practice, especially monitor these cases with at least one known gene abnormality. Here, we reviewed the evidence of ctDNA in NSCLC and consider possible future applications in patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Society AC. Cancer facts and figures. 2012.

  2. Jemal A et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.

    Article  PubMed  Google Scholar 

  3. Reade CA, Ganti AK. EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biogeosciences. 2009;3:215–24.

    CAS  Google Scholar 

  4. Agarwal M et al. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer. 2010;68(3):398–402.

    Article  PubMed  Google Scholar 

  5. Ulivi P et al. Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One. 2013;8(2):e57401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Catarino R et al. Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PLoS One. 2012;7(6):e38559.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Diaz Jr LA et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Lee YJ et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res. 2011;17(15):5179–87.

    Article  CAS  PubMed  Google Scholar 

  9. Pan S et al. Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer? Biomed Pharmacother. 2012;66(2):131–7.

    Article  CAS  PubMed  Google Scholar 

  10. Szpechcinski A et al. Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC. Expert Opin Biol Ther. 2012;12 Suppl 1:S3–9.

    Article  CAS  PubMed  Google Scholar 

  11. van der Vaart M, Pretorius PJ. The origin of circulating free DNA. Clin Chem. 2007;53(12):2215.

    Article  PubMed  Google Scholar 

  12. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–37.

    Article  CAS  PubMed  Google Scholar 

  13. Viorritto IC, Nikolov NP, Siegel RM. Autoimmunity versus tolerance: can dying cells tip the balance? Clin Immunol. 2007;122(2):125–34.

    Article  CAS  PubMed  Google Scholar 

  14. Fleischhacker M, Schmidt B. Cell-free DNA resuscitated for tumor testing. Nat Med. 2008;14(9):914–5.

    Article  CAS  PubMed  Google Scholar 

  15. Bendich A, Wilczok T, Borenfreund E. Circulating DNA as a possible factor in oncogenesis. Science. 1965;148(3668):374–6.

    Article  CAS  PubMed  Google Scholar 

  16. Leon SA et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–50.

    CAS  PubMed  Google Scholar 

  17. Kumar S et al. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer. Eur Respir J. 2010;36(4):885–92.

    Article  CAS  PubMed  Google Scholar 

  18. Sirera R et al. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(2):286–90.

    Article  PubMed  Google Scholar 

  19. Vinayanuwattikun C et al. The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer. J Cancer Res Clin Oncol. 2013;139(1):67–76.

    Article  CAS  PubMed  Google Scholar 

  20. Ludovini V et al. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J Thorac Oncol. 2008;3(4):365–73.

    Article  PubMed  Google Scholar 

  21. Yoon KA et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn. 2009;11(3):182–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Szpechcinski A et al. Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls. Eur J Med Res. 2009;14 Suppl 4:237–40.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Paci M et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer. 2009;64(1):92–7.

    Article  PubMed  Google Scholar 

  24. Roth C et al. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol. 2011;5(3):281–91.

    Article  CAS  PubMed  Google Scholar 

  25. Camps C et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer. 2011;72(3):365–9.

    Article  PubMed  Google Scholar 

  26. Jian G et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(9):1341–7.

    Article  PubMed  Google Scholar 

  27. He C et al. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer. 2009;125(10):2393–9.

    Article  CAS  PubMed  Google Scholar 

  28. Zhang L et al. Detection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technology. Curr Drug Metab. 2012;13(7):1007–11.

    Article  CAS  PubMed  Google Scholar 

  29. Zhao X et al. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I–IV non-small cell lung cancer patients. Respiration. 2013;85(2):119–25.

    Article  CAS  PubMed  Google Scholar 

  30. Kimura H et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol. 2006;1(3):260–7.

    Article  PubMed  Google Scholar 

  31. Wang S et al. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(4):1324–30.

    Article  CAS  PubMed  Google Scholar 

  32. Nygaard AD et al. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 2013;79(3):312–7.

    Article  PubMed  Google Scholar 

  33. Kim ST et al. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? Am J Clin Oncol. 2013;36(1):57–63.

    Article  CAS  PubMed  Google Scholar 

  34. Bai H et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 2009;27(16):2653–9.

    Article  CAS  PubMed  Google Scholar 

  35. Yung TK et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009;15(6):2076–84.

    Article  CAS  PubMed  Google Scholar 

  36. Narayan A et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 2012;72(14):3492–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Angulo B et al. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS One. 2012;7(8):e43842.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Sheffield VC et al. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics. 1993;16(2):325–32.

    Article  CAS  PubMed  Google Scholar 

  39. Cohen V et al. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer. 2006;107(12):2858–65.

    Article  CAS  PubMed  Google Scholar 

  40. Li M, Stoneking M. A new approach for detecting low-level mutations in next-generation sequence data. Genome Biol. 2012;13(5):R34.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lynch TJ et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.

    Article  CAS  PubMed  Google Scholar 

  42. Paez JG et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.

    Article  CAS  PubMed  Google Scholar 

  43. http://www.cancer.gov/cancertopics/druginfo/fda-erlotinib-hydrochloride.

  44. Mack PC et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009;4(12):1466–72.

    Article  PubMed  Google Scholar 

  45. Punnoose EA et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012;18(8):2391–401.

    Article  CAS  PubMed  Google Scholar 

  46. Tsao DA et al. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients. Lung Cancer. 2010;68(1):51–7.

    Article  PubMed  Google Scholar 

  47. Salazar F et al. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer. 2011;72(1):84–91.

    Article  PubMed  Google Scholar 

  48. Kuang Y et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res. 2009;15(8):2630–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Kimura H et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007;97(6):778–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Kimura H et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res. 2006;12(13):3915–21.

    Article  CAS  PubMed  Google Scholar 

  51. Goto K et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol. 2012;7(1):115–21.

    Article  CAS  PubMed  Google Scholar 

  52. Isobe K et al. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res. 2012;32(8):3339–44.

    PubMed  Google Scholar 

  53. Nakamura T et al. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol. 2012;7(9):1369–81.

    Article  CAS  PubMed  Google Scholar 

  54. Brevet M et al. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer. 2011;73(1):96–102.

    Article  PubMed  Google Scholar 

  55. Jiang B et al. Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res. 2011;39(4):1392–401.

    Article  CAS  PubMed  Google Scholar 

  56. Bai H et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(25):3077–83.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Janne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer. 2008;60 Suppl 2:S3–9.

    Article  PubMed  Google Scholar 

  58. Pao W et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Suda K et al. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol. 2009;4(1):1–4.

    Article  PubMed  Google Scholar 

  60. Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis. 2011;3(1):10–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Inukai M et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006;66(16):7854–8.

    Article  CAS  PubMed  Google Scholar 

  62. Kris MG, Simon GR. Maintenance therapy for non-small cell lung cancer. The NCCN 15th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care. 2010.

  63. FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. U.S. Food and Drug Administration.http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm.

  64. Califano R, Landi L, Cappuzzo F. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs. 2012;72 Suppl 1:28–36.

    Article  CAS  PubMed  Google Scholar 

  65. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-Small Cell Lung Cancer V2. 2012.

  66. Keedy VL et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29(15):2121–7.

    Article  PubMed  Google Scholar 

  67. Carpagnano GE et al. 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer. Am J Respir Crit Care Med. 2008;177(3):337–41.

    Article  CAS  PubMed  Google Scholar 

  68. Sirera R et al. Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer. Lung Cancer. 2008;61(1):104–8.

    Article  PubMed  Google Scholar 

  69. Toth G, Gaspari Z, Jurka J. Microsatellites in different eukaryotic genomes: survey and analysis. Genome Res. 2000;10(7):967–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Speicher MR. Microsatellite instability in human cancer. Oncol Res. 1995;7(6):267–75.

    CAS  PubMed  Google Scholar 

  71. Silva JM, Bonilla F, Correspondence re: Coulet F et al. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res. 2000;60:707–9. Cancer Res. 2001;61(23):8595–6.

  72. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21(35):5427–40.

    Article  CAS  PubMed  Google Scholar 

  73. Zhang Y et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 2011;303(1):21–8.

    Article  CAS  PubMed  Google Scholar 

  74. Fischer JR et al. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer. 2007;56(1):115–23.

    Article  PubMed  Google Scholar 

  75. Lee SM, Park JY, Kim DS. Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer. Mol Cells. 2012;34(2):171–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Ponomaryova AA et al. RARbeta2 gene methylation level in the circulating DNA from blood of patients with lung cancer. Eur J Cancer Prev. 2011;20(6):453–5.

    Article  CAS  PubMed  Google Scholar 

  77. Vinayanuwattikun C et al. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(11):1818–25.

    Article  PubMed  Google Scholar 

  78. Zhang Y et al. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer. Clin Lung Cancer. 2010;11(4):264–70.

    Article  CAS  PubMed  Google Scholar 

  79. Zhang YW et al. Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma. 2010;57(3):228–33.

    Article  CAS  PubMed  Google Scholar 

  80. Hoffmann AC et al. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. J Surg Oncol. 2009;100(5):414–7.

    Article  CAS  PubMed  Google Scholar 

  81. Zhang Y et al. Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci. 2010;101(4):934–40.

    Article  CAS  PubMed  Google Scholar 

  82. Hoffmann AC et al. Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol. 2009;135(9):1231–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by the National Natural Science Foundation of China (no. 81202739).

Author information

Authors and Affiliations

  1. First Teaching Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China

    Kun Nie, Yujie Jia & Xuezhu Zhang

Authors
  1. Kun Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yujie Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xuezhu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xuezhu Zhang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nie, K., Jia, Y. & Zhang, X. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumor Biol. 36, 7–19 (2015). https://doi.org/10.1007/s13277-014-2758-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2758-3

Keywords

Search

Navigation